image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 14.62
-2.86 %
$ 844 M
Market Cap
12.5
P/E
1. INTRINSIC VALUE

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.[ Read More ]

The intrinsic value of one EMBC stock under the base case scenario is HIDDEN Compared to the current market price of 14.6 USD, Embecta Corp. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EMBC

image
FINANCIALS
1.12 B REVENUE
-0.77%
222 M OPERATING INCOME
-28.46%
70.4 M NET INCOME
-68.52%
67.7 M OPERATING CASH FLOW
-83.58%
-26.5 M INVESTING CASH FLOW
-10.42%
-48.7 M FINANCING CASH FLOW
-1.46%
272 M REVENUE
-5.12%
55.9 M OPERATING INCOME
-22.14%
14.7 M NET INCOME
-49.13%
-2.1 M OPERATING CASH FLOW
-8.64%
-9.7 M INVESTING CASH FLOW
-185.29%
-11.5 M FINANCING CASH FLOW
2.54%
Balance Sheet Decomposition Embecta Corp.
image
Current Assets 749 M
Cash & Short-Term Investments 326 M
Receivables 17.9 M
Other Current Assets 405 M
Non-Current Assets 465 M
Long-Term Investments 0
PP&E 323 M
Other Non-Current Assets 142 M
Current Liabilities 354 M
Accounts Payable 53.5 M
Short-Term Debt 13.1 M
Other Current Liabilities 287 M
Non-Current Liabilities 1.68 B
Long-Term Debt 1.64 B
Other Non-Current Liabilities 41.8 M
EFFICIENCY
Earnings Waterfall Embecta Corp.
image
Revenue 1.12 B
Cost Of Revenue 371 M
Gross Profit 750 M
Operating Expenses 528 M
Operating Income 222 M
Other Expenses 151 M
Net Income 70.4 M
RATIOS
66.91% GROSS MARGIN
66.91%
19.76% OPERATING MARGIN
19.76%
6.28% NET MARGIN
6.28%
-8.57% ROE
-8.57%
5.80% ROA
5.80%
18.87% ROIC
18.87%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Embecta Corp.
image
Net Income 70.4 M
Depreciation & Amortization 32.6 M
Capital Expenditures -26.5 M
Stock-Based Compensation 21.5 M
Change in Working Capital -80 M
Others -57.2 M
Free Cash Flow 41.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Embecta Corp.
image
Wall Street analysts predict an average 1-year price target for EMBC of $12 , with forecasts ranging from a low of $12 to a high of $12 .
EMBC Lowest Price Target Wall Street Target
12 USD -17.92%
EMBC Average Price Target Wall Street Target
12 USD -17.92%
EMBC Highest Price Target Wall Street Target
12 USD -17.92%
4. DIVIDEND ANALYSIS
1.20% DIVIDEND YIELD
0.15 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Embecta Corp.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
32.5 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
9 months ago
Feb 12, 2024
Bought 32.5 K USD
Melcher David F
Director
+ 2000
16.25 USD
1 year ago
Sep 08, 2023
Bought 98.3 K USD
Melcher David F
Director
+ 6233
15.7662 USD
1 year ago
Aug 10, 2023
Bought 109 K USD
Kurdikar Devdatt
President and CEO
+ 5000
21.81 USD
1 year ago
Aug 10, 2023
Bought 102 K USD
Mann Jeffrey Z
SVP, GC, Head Corp. Dev., Secy
+ 4700
21.67 USD
1 year ago
Aug 10, 2023
Bought 100 K USD
Elguicze Jacob
SVP and CFO
+ 4625
21.6637 USD
1 year ago
Feb 15, 2023
Bought 102 K USD
Melcher David F
Director
+ 3100
32.925 USD
1 year ago
Feb 15, 2023
Bought 101 K USD
Melcher David F
Director
+ 3100
32.51 USD
7. News
UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 26, 2024. globenewswire.com - 4 days ago
embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Thursday, November 26, 2024. globenewswire.com - 4 days ago
embecta Celebrates National Diabetes Awareness Month by Ringing Nasdaq Closing Bell embecta will be joined by diabetes advocacy groups to ring the Nasdaq Closing Bell today in recognition of National Diabetes Awareness Month in November. globenewswire.com - 1 week ago
Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes. zacks.com - 2 months ago
embecta Announces FDA Clearance of its Disposable Patch Pump for Insulin Delivery Informed by the Unique Needs of People with Type 2 Diabetes embecta has received 510(k) clearance from the FDA for its proprietary disposable insulin delivery system, a patch pump with a 300-unit insulin reservoir. globenewswire.com - 2 months ago
embecta to Participate in Investor Events PARSIPPANY, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that management will participate in the following investor events: globenewswire.com - 2 months ago
Embecta Corp. (EMBC) Just Overtook the 200-Day Moving Average From a technical perspective, Embecta Corp. (EMBC) is looking like an interesting pick, as it just reached a key level of support. EMBC recently overtook the 200-day moving average, and this suggests a long-term bullish trend. zacks.com - 3 months ago
Embecta Corp. (EMBC) Q3 2024 Earnings Call Transcript Embecta Corp. (NASDAQ:EMBC ) Q3 2024 Earnings Conference Call August 9, 2024 8:00 AM ET Company Participants Pravesh Khandelwal - VP & Head of IR Dev Kurdikar - President, CEO & Director Jake Elguicze - SVP & CFO Conference Call Participants Marie Thibault - BTIG Travis Steed - Bank of America Securities Kristen Stewart - CL King Michael Polark - Wolfe Research Operator Please stand by. Welcome ladies and gentlemen to the Fiscal Third Quarter 2024 Embecta Earnings Conference Call. seekingalpha.com - 3 months ago
Embecta Corp. (EMBC) Tops Q3 Earnings and Revenue Estimates Embecta Corp. (EMBC) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.69 per share a year ago. zacks.com - 3 months ago
Embecta Corp. Reports Third Quarter Fiscal 2024 Financial Results PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2024. globenewswire.com - 3 months ago
embecta Announces Quarterly Cash Dividend PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024 to stockholders of record at the close of business on August 27, 2024. globenewswire.com - 3 months ago
Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company Genpact's deep domain knowledge and data expertise enables embecta's vision to make a meaningful impact in the healthcare sector NEW YORK , July 29, 2024 /PRNewswire/ -- Genpact (NYSE: G), a global professional services and solutions firm delivering outcomes that shape the future, has been working with embecta (Nasdaq: EMBC), a global diabetes care company, to support its spin-off from Becton Dickinson and Company (BD) and subsequent evolution as an independent leader in the diabetes technology market. "Genpact's deep expertise in the life sciences and healthcare sectors enables us to leverage extensive knowledge alongside our capabilities in data, technology, and AI. prnewswire.com - 3 months ago
8. Profile Summary

Embecta Corp. EMBC

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 844 M
Dividend Yield 1.20%
Description Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Contact 300 Kimball Drive, Parsippany, NJ, 07054 https://www.embecta.com
IPO Date March 22, 2022
Employees 2200
Officers Mr. Devdatt Kurdikar President, Chief Executive Officer & Director Mr. Slobodan Radumilo Senior Vice President & President of International Mr. Jeffrey Z. Mann Senior Vice President, General Counsel, Head of Business Development & Corporate Secretary Mr. Shaun Curtis Senior Vice President of Global Manufacturing & Supply Chain Ms. Colleen Riley Senior Vice President & Chief Technology Officer Mr. Pravesh Khandelwal Vice President & Head of Investor Relations Ms. Ginny Blocki Senior Vice President of Global Marketing & Product Management Ms. Jean M. Casner Senior Vice President & Chief Human Resources Officer Mr. Tom Blount Senior Vice President & President of North America Mr. Jacob P. Elguicze Senior Vice President & Chief Financial Officer